Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the second quarter and first half of 2020. From April 2020 to June 2020, the company estimates that the net profit attributable to shareholders of the Company to be in the range of RMB 291.1093 million and RMB 345.7495 million. For the first half, the company expects net profit attributable to shareholders of the Company of RMB 546.4020 million­ to RMB 601.0422 million and basic earnings per share of RMB 0.4381 per share­ to RMB 0.4819 per share.